848310-98-5 Usage
General Description
3-(3-Bromophenyl)-4-(4-chlorophenyl)butan-2-one is a chemical compound with the molecular formula C16H14BrClO. It is a ketone derivative with a bromine-substituted phenyl group and a chlorine-substituted phenyl group attached to a butanone backbone. 3-(3-Bromophenyl)-4-(4-chlorophenyl)butan-2-one may be used in various chemical reactions and organic synthesis processes. It is important to handle this compound with caution and follow proper safety measures when working with it due to its potential reactivity and hazard properties.
Check Digit Verification of cas no
The CAS Registry Mumber 848310-98-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,4,8,3,1 and 0 respectively; the second part has 2 digits, 9 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 848310-98:
(8*8)+(7*4)+(6*8)+(5*3)+(4*1)+(3*0)+(2*9)+(1*8)=185
185 % 10 = 5
So 848310-98-5 is a valid CAS Registry Number.
InChI:InChI=1/C16H14BrClO/c1-11(19)16(13-3-2-4-14(17)10-13)9-12-5-7-15(18)8-6-12/h2-8,10,16H,9H2,1H3
848310-98-5Relevant articles and documents
SUBSTITUTED ESTERS AS CANNABINOID-1 RECEPTOR MODULATORS
-
Page/Page column 57, (2008/06/13)
Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present in
RADIOLABELED CANNABINOID-1 RECEPTOR MODULATORS
-
Page/Page column 32, (2010/02/10)
The present invention relates to particular radiolabeled Cannabinoid-1 (CB1) receptor modulators, and methods of using these modulators for labeling and diagnostic imaging of Cannabinoid-1 receptors in mammals, particularly humans. In addition, intermediates useful for the synthesis of the radiolabeled Cannabinoid-1 receptor modulators are also disclosed, as well as the processes for synthesizing the radiolabeled Cannabinoid-1 receptor modulators. Still further, formulations of the radiolabeled Cannabinoid-1 receptor compounds are described.